Krystal Biotech Inc (KRYS)

Debt-to-capital ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	799,242	778,641	755,948	653,114	489,566	522,231	540,772	559,181	548,554	593,576	408,237	418,540	430,652	292,084	301,720	309,696	198,369	202,914	207,646	198,290
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

March 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $799,242K)
= 0.00

The debt-to-capital ratio of Krystal Biotech Inc has consistently been reported as 0.00 for all the periods listed. This indicates that the company has not used any debt to finance its operations and investments, relying solely on capital from equity sources. A debt-to-capital ratio of 0.00 reflects a strong financial position in terms of solvency and financial risk, as there is no financial leverage present in the company's capital structure. However, it is important to note that a zero debt-to-capital ratio may also suggest limited access to the tax benefits associated with debt financing. Krystal Biotech's consistent zero debt-to-capital ratio suggests a conservative financial strategy with an emphasis on equity funding.